Senti Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
Logic gating and gene circuits enable selective cancer cell targeting in AML, with SENTI-202 showing a 42% CR/CRh rate, strong safety, and rapid hematopoietic recovery in phase I. RMAT designation supports a single-arm registrational trial, and expansion into new indications and modalities is planned.
-
Logic-gated cell therapy SENTI-202 showed high response rates and deep, durable remissions in relapsed/refractory AML, with a favorable safety profile and broad patient eligibility. Plans are underway for a pivotal trial and expansion into new indications, with strong physician and regulatory interest.
Fiscal Year 2025
-
Senti 202, an off-the-shelf logic-gated CAR-NK therapy, showed a 50% ORR and 42% CR/CRh rate with high MRD negativity and excellent safety in heavily pretreated relapsed/refractory AML patients. The therapy's unique NOT gate mechanism preserves healthy cells, supporting rapid recovery and broad applicability.
-
SENTI-202, a logic-gated CAR NK cell therapy, demonstrated promising safety and efficacy in relapsed/refractory AML, with high response rates and MRD negativity. The platform is expanding to solid tumors and will present more robust data on ~20 patients by year-end.
-
SENTI-202, an off-the-shelf logic-gated NK cell therapy for AML, demonstrated strong safety and efficacy in phase 1, with 57% complete remission and 100% MRD-negative responses. Additional data and pipeline expansion are expected by year-end.
-
Logic Gate technology enables selective cancer cell targeting, with SENTI-202 showing strong efficacy and safety in relapsed/refractory AML. Durable responses and healthy cell protection were observed, with plans to expand into new indications and solid tumors later this year.
-
Senti's Logic Gate technology enables precise targeting of cancer cells while sparing healthy cells, with early clinical data in AML showing strong efficacy, safety, and durability. The platform supports off-the-shelf manufacturing and has potential applications beyond hematological cancers.
-
Logic gating technology enables multi-antigen targeting in oncology, with SENTI-202 showing promising efficacy and safety in relapsed/refractory AML. The platform is expanding into solid tumors and other hematologic indications, supported by recent investments and an experienced leadership team.
-
Senti 202, a logic-gated CAR-NK cell therapy for relapsed/refractory AML, showed strong safety and promising efficacy, with high response rates and durable remissions in a high-risk population. The therapy selectively targets cancer cells while sparing healthy cells, and further expansion of the trial is planned.
-
SENTI-202, an off-the-shelf NK cell therapy using logic gate technology, showed promising initial results in relapsed/refractory AML, with two of three patients achieving durable, MRD-negative complete responses. The company plans to enroll about 20 patients in phase I and will present further data at AACR.
Fiscal Year 2024
-
The session highlighted a gene circuit platform enabling multi-target cell therapies, with SENTI-202 in phase I for AML and initial data expected by year-end. SENTI-301A targets liver cancer, with first data in 2025. Strategic collaborations, a dedicated CDMO, and a strong cash position support ongoing development.
-
Next-generation cell and gene therapies are advancing with SENTI-202 for AML and SENTI-301A for liver cancer, both leveraging proprietary Logic Gate and multi-arming technologies. Initial clinical data for SENTI-202 is expected by year-end 2024, with platform expansion into solid tumors anticipated.